Microsoft MAI-DxO Tops Generalist Doctors 83% to 36% in Science
Microsoft's MAI-DxO diagnosed 83.2% of hard NEJM cases vs 36.1% for generalists in a peer-reviewed Science study. It was a simulation, not live clinical use.
Artificial intelligence is moving deeper into clinical practice, promising faster and potentially more accurate ways to detect disease, interpret scans, and support treatment decisions. What began as experimental research is now showing up in radiology suites, pathology labs, and primary care workflows, as software tools analyze images, flag abnormalities, and help clinicians prioritize cases that need urgent attention.
This space matters now because the pace of deployment is outrunning traditional regulatory frameworks. Agencies like the FDA are reassessing how to classify and monitor AI-driven diagnostic tools, especially as generative AI models introduce new capabilities—and new risks—that don't fit neatly into existing device categories. At the same time, questions about data ownership, patient privacy, and who controls the vast troves of health information needed to train these systems are becoming central to the industry's future. Efforts to decentralize or democratize medical data access are emerging as a counterweight to concentrated control by large health systems and tech companies.
Beyond the technology itself, there's growing debate about how AI changes clinical training and judgment. Tools like AI scribes and diagnostic assistants raise concerns about whether clinicians are learning from these systems or becoming overly dependent on them, potentially eroding skills over time. Meanwhile, patients and survivors themselves are entering the space, building platforms designed to help others navigate diagnosis and treatment more effectively.
Readers here will find ongoing coverage of regulatory shifts, new diagnostic tools entering the market, debates over safety and accountability, and the human stories behind AI's expanding role in medicine—from startups and hospitals to patients advocating for better tools and more equitable access to their own health data.
Microsoft's MAI-DxO diagnosed 83.2% of hard NEJM cases vs 36.1% for generalists in a peer-reviewed Science study. It was a simulation, not live clinical use.
Microsoft's MAI-DxO hit 83% on hard NEJM cases vs 36% for generalist doctors in a Science paper, but it's untested on patients and FDA rules are unclear.
Microsoft's MAI-DxO diagnosed 83% of complex NEJM cases vs 36% for generalist doctors in a Science study. It was a text-only benchmark, not a clinical trial.
A Science study found Microsoft's MAI-DxO diagnosed hard cases with 83% accuracy vs 36% for generalist doctors. Hospital trials come next, but FDA rules lag.
A new systematic review finds US hospital AI is outpacing oversight, citing four gaps from weak post-market monitoring to unclear liability.
FDA AI device list tops 1,600 entries, mostly radiology, and the agency kept 510(k) review for imaging AI, while hospitals now carry most clinical AI oversight.
With FDA's AI device list above 1,600, experts say hospitals must test clinical AI inside real workflows, monitor it after launch and rehearse outage plans.
Northwestern Medicine embedded OpenEvidence's AI evidence tool in Epic on Oct. 8, giving nurses and pharmacists access as FDA rules leave such tools unreviewed.
Kaiser, Cleveland Clinic, HCA and Mayo lead hospital AI as the FDA's AI device list reaches 1,614, 76% in radiology, and January rules loosen oversight.
A multicenter study in European Radiology finds DeepHealth's FDA-cleared Prostate AI, combined with radiologist MRI reads, could avoid 18.9% of biopsies while
Microsoft's MAI-DxO diagnosed 83% of hard cases vs 36% for generalist doctors in a Science study, as FDA weighs rules for generative AI devices.
A Science study found OpenAI's o1 beat two internists at diagnosing 76 real ER patients (67% vs. 50–55%), while FDA rules for such tools remain unsettled.
Microsoft's MAI-DxO scored 83% vs 36% for generalist doctors in a Science study and moves to a Boston hospital trial, though no generative AI diagnostic has
The FDA asked for public comment on regulating generative AI medical devices through October 19, 2026, but it left hospital monitoring capacity unresolved.
Hospitals are scaling AI scribes and imaging platforms as the FDA's AI device list hits 1,614 and looser CDS rules shift vetting onto health systems.
xAID published its own ranking of seven AI radiology platforms for teleradiology groups and placed itself first, ahead of Aidoc, Viz.ai, Rad AI and Qure.ai.
Imaging AI shows trial-backed accuracy gains and FDA counts exceed 1,600 devices, while chatbots lag and new guidance shifts AI vetting to hospitals.
The FDA has now authorized over 1,600 AI medical devices, 76% of them in radiology. Hospitals use AI widely, but fewer than 20% use it well for core diagnosis.
Health systems signed enterprise AI deals in 2026 as FDA-listed AI devices hit 1,614, mostly radiology, and new FDA guidance eased decision-support oversight.
A Northwell study of 3,856 brain CT scans found Aidoc's FDA-cleared AI flagged 55 aneurysms radiologists missed, a 39% gain, but fell short in outpatient care.
FDA has cleared 1,451 AI medical devices as insurers and lawyers weigh untested malpractice liability risks heading into 2026.
A Harvard-led Science study finds AI beat doctors on diagnosis and ER triage tasks, fueling debate over regulation and clinical readiness.
FDA opened public comment on regulating generative AI medical devices, proposing risk tiers and doctor-style competency testing by Oct. 19, 2026.
BioGen AI's MedSense claims to outdiagnose doctors, fueling debate over AI's expanding, loosely regulated role in hospitals.
Intermountain Medical Center becomes the second US hospital to deploy an AI-enhanced MRI machine that speeds scans and sharpens images.
Democrats sign an AI regulation pledge as the FDA seeks feedback on AI medical devices amid mental health AI lawsuits and healthcare ROI debates.
A Pennsylvania lawsuit and new FDA feedback push highlight gaps in mental health AI oversight and trust.
FDA's 2026 guidance exempts more AI decision tools from review as Harvard and Nature studies show AI matching doctors, shifting validation to hospitals.
AI radiology tools promise faster reports amid a radiologist shortage, but FDA oversight and outcome data still lag behind adoption.
AI's rapid healthcare adoption faces scrutiny after a Mayo Clinic lawsuit alleges a 67% diagnostic error rate, raising oversight concerns.